Research focus

Clinical Pharmacology Unit (CPU) is certified Unit working under ISO 9001, GCP and national legislation. It executes clinical trials with pharmaceuticals or medical devices (phases I., II., III. and IV.). Main interest is pharmacokinetics (PK) and pharmacodynamics (PD) of the drug and its early phase of development. In this field, CPU realizes sponsored and academic studies. Latest academic trial was to study the influence of different application drug form used in intensive care unit during nasogastric tube (NGT) applications. One of the topics on CPU is the handling and monitoring of sepsis in intensive care. Other study topics are from the field of rheumatology (Phase I), gastroenterology (Phase II), diabetology (Phase I) and oncology (Phase I). As an important step to provide IIT clinical trials, the unit prepares their own protocols. From 2019 CPU develops clinical cannabis research as a first Centre in Czech Republic. Cannabis growing and medicament production is GMP and GACP certified.  

 

Research objectives

  • To change Pk/Pd of the drugs primarily in critically ill
  • To improve the results of perioperative care in high-risk patients
  • To grow medical cannabis in GMP standard
  • To produce new forms of cannabis in Hospital pharmacy
  • To study cannabis effect on patients (current/new)
  • To study and confirm cannabis product safety
  • Contract research

Main partners

  • Masaryk Memorial Cancer Institute, Brno, Czech Republic Thomayer Hospital, Prague, Czech Republic, Masaryk University Brno, Czech Republic
  • University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic

Technological equipment

  • Fully equipped clean spaces for providing of clinical trials (A-D grade) certified by State Institute for Drug Control
  • Fully equipped Clinical Pharmacology Unit (5 haemodynamically monitored beds) with educated professional Intensive Care Unit 
  • HPLC, ROTEM centrifuges, freezers (-20 and -80 °C) and refrigerators
  • Electrical Impedance Tomography (EIT)

Offered services and expertise

  • Complete servis for conducting clinical trials
  • Pk/Pd of various drugs in different patient groups and diseases
  • Sepsis in the critically ill
  • Monitoring of haemodynamics (invasive – noninvasive)

Top publications

  • Zvonicek, V., Jurak, P., Halamek, J., Kruzliak, P., Vondra, V., Leinveber, P., Cundrle, I., Pavlik, M., Suk, P., Sramek, V. The impact of sedation on pulse pressure variation. Australian Critical Care. 2015, 28(4), 203-207.
  • Ruzsikova, A., Souckova, L., Suk, P., Opatrilova, R., Kejdusova, M., Sramek, V., Quantitative analysis of drug losses administered via nasogastric tube - In vitro study. International Journal of Pharmaceutics. 2015, 478 (1), 368-371.
  • Rautanen, A., Mills, T. C., Gordon, A. C., Hutton, P., Steffens, M., Nuamah, R., Chiche, J.-D., Parks, T., Chapman, S. J., Davenport, E. E., Elliott, K. S., Bion, J., Lichtner, P., Meitinger, T., Wienker, T. F., Caulfield, M. J., Mein, C., Bloos, F., Bobek, I., Cotogni, P., Sramek, V., Sarapuu, S., Kobilay, M., Ranieri, V. M., Rello, J., Sirgo, G., Weiss, Y. G., Russwurm, S., Schneider, E. M., Reinhart, K., Holloway, P. A. H.,Knight, J. C., Garrard, C. S., Russell, J. A., Walley, K. R., Stueber, F., Hill, A. V. S., Hinds, C. J., Investigators, E.-E. G., Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respiratory Medicine. 2015, 3 (1), 53-60.
  • Cundrle, I., Jr., Sramek, V., Pavlik, M., Suk, P., Radouskova, I., Zvonicek, V., Temperature corrected thromboelastography in hypothermia. Is it necessary? European Journal of Anaesthesiology. 2013, 30 (2), 85-89.
  • Souckova, L.,Opatrilova, R., Suk, P., Cundrle, I., Jr., Pavlik, M., Zvonicek, V., Hlinomaz, O., Sramek, V., Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). European Journal of Clinical Pharmacology. 2013, 69 (3), 309-317.

Other selected results

  • Clopidogrel is not absorbed in cardiac patients after CPR (see publ. Součková et al. 2013)
  • There are significant losses of the drugs given via NGT. Losses are dependent on the method of preparation/application (see publ. Zvoníček et al. 2015)
  • CVVH with citrate anticoagulation is feasible for the treatment of hypercalcemia with AKI (see publ. Šrámek et al. 1998)

Team members

  • MVDr. Ing. Václav Trojan, Ph.D.
  • Libuše Martináková, MBA
  • MUDr. Pavel Suk, Ph.D.
  • Bc. Markéta Beranová
  • Mgr. Marta Holíková
  • MUDr. Radovan Hřib
  • PharmDr. Adriána Papiež, Ph.D.
  • PharmDr. Jitka Rychlíčková, Ph.D.
  • MUDr. Jiří Škopek, Ph.D.
  • Ing. Martin Vašek

Principal Investigator

MVDr. Ing. Václav Trojan, Ph.D.
MVDr. Ing. Václav Trojan, Ph.D.
Head of CF
Phone: +420 54 318 4046

Assistant

Libuše Martináková, MBA
Libuše Martináková, MBA
Study Coordinator
Phone: +420 54 318 5492